Recent Updates
Recently added Catalysts
LAB Positive Sentiment

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Tuesday, October 21, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Standard BioTools Inc. announced it will publish its third quarter financial results on November 4, 2025, after the market closes. As a leading solutions provider, the company utilizes advanced technologies to aid biomedical researchers in accelerating the development of better medicines. Their proprietary methodologies are essential in various fields including oncology and immunotherapy, reflecting their commitment to improving patient outcomes.
Price reaction · baseline $1.28 (2025-10-20 close) · hit after-hours · clean, no other LAB news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Standard BioTools is reporting upcoming financial results, indicating ongoing business activity.
  • The company is a leader in providing next-generation technologies crucial for biomedical research.
  • Their products aim to improve patient outcomes in significant fields like oncology and immunology.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Frequently Asked Questions

When will Standard BioTools release Q3 2025 financial results?

Standard BioTools will publish its Q3 2025 financial results on November 4, 2025.

What technologies does Standard BioTools specialize in?

Standard BioTools specializes in next-generation technologies like SomaScan, mass cytometry, and microfluidics.

Who collaborates with Standard BioTools?

Standard BioTools collaborates with academic, government, and clinical laboratories globally.

What research areas does Standard BioTools focus on?

The company focuses on oncology, immunology, and immunotherapy in translational research.

Are Standard BioTools products for diagnostic use?

No, Standard BioTools products are for Research Use Only and not for diagnostic procedures.

ShareAdd on Google
Tags: LAB Viatris Investor Conferences Healthcare Standard BioTools financial results biomedical research clinical research
Last updated: Oct 21, 2025

Biotech snapshot

Cash runway
$477M liquidity · $3M/mo burn
~137 mo
Minimal dilution risk